

CONFERENCE PROGRAM

Sunday, 2 October 2016

Sunday, 2 October 2016			
08:00-19:00	Registration		
9:30-9:55	Coffee Social (<i>Foyer of Grand Ballroom</i>)		Sponsored by EpiVax, Inc.
9:55-10:00	Opening Remarks (<i>Grand Ballroom</i>) ISV Congress Co-chairs: Margaret Liu, David Weiner, Anne De Groot		
10:00-12:15	Plenary Session One: Vaccine Challenges (<i>Grand Ballroom</i>) Session Chairs: Shan Lu and Margaret Liu		
10:00-10:30	[PL1.1] The Ebola Disaster and How to Prevent it from Happening Again Stanley Plotkin, <i>VaxConsult</i>		
10:30-11:00	[PL1.2] Development of V920, Live, Attenuated Recombinant Vesicular Stomatitis Vaccine Against Ebola Zaire (rVSV-ZEBOV) Tom Monath, <i>New Link Genetics</i>		
11:00-11:30	[PL1.3] Chimpanzee Adenoviral Vectors as Vaccines: from Alphaviruses to Zika Adrian Hill, <i>Oxford University</i>		
11:30-12:15	[PL1.4] Panel: Challenges of Making Emerging Diseases Vaccines Session Chair: Stanly Plotkin, <i>VaxConsult</i> Panelists: Phil Krause, <i>Food and Drug Administration</i> , Rip Ballou, <i>GSK</i> Adrian Hill, <i>Oxford University</i> , Tom Monath, <i>New Link Genetics</i>		
12:15-13:30	Lunch (<i>Harbor View Ballroom and Commonwealth Ballroom</i>)		Sponsored by Ichor Medical System, Inc.
13:30-15:30	Concurrent Session 1: Mechanisms of Immune Efficacy Session Chairs: Nik Petrovksy and Peter Nara	Concurrent Session 2: DNA Vaccines Session Chair: David Weiner Sponsored by: Inovio Pharmaceuticals Sponsored by: Eurogentec	Concurrent Session 3: Zoonoses and Animal Models for Evaluating Vaccine Protection Session Chairs: Cyril Gay and Bin Wang
13:30-14:00	Towards a Universal Influenza Virus Vaccine Adolfo Garcia-Sastre, <i>Icahn School of Medicine at Mount Sinai</i>	[O2.1] Developments in EID Joel Maslow, <i>GeneOne</i>	[O3.1] Immunotherapeutic Approaches for Alzheimer and Prion Diseases Thomas Wizniewski, <i>NYU School of Medicine</i>
14:00-14:15	[O1.2] The generation of an immunogenic second-generation conserved segment HCV T-cell vaccine to target multiple HCV genotypes. Timothy Donnison, <i>Oxford Univ.</i>	[O2.2] Developments in RNA Vaccines. Hari Pujar, <i>Moderna Therapeutic</i>	[O3.2] Prevention of emerging zoonoses in Central Africa: an overview from a veterinary perspective. Emmanuel Assana, <i>University of Ngaoundéré</i>
14:15-14:30	[O1.3] HSV-2 vaccine virus deleted in glycoprotein D (Δ gD-2) elicits high-titer IgG2 antibodies that activate the FcR and protect mice and guinea pigs from skin or vaginal challenge with clinical isolates of HSV-1 and HSV-2, and prevent the establishment of latency. William R. Jacobs, Jr., <i>Howard Hughes Medical Institute, Albert Einstein College of Medicine</i>		[O3.3] The enhanced immune responses of pig to PCV-2 vaccine by inoculation with chitosan nanoparticles of recombinant pig interleukin-23 gene. Yongle Xiao, <i>Sichuan University</i>
14:30-14:45	[O1.4] Immunogenicity and Efficacy of a Trivalent HSV-2 gC2/gD2/gE2 Subunit Antigen Vaccine in Rhesus Macaques and Guinea Pigs Harvey Friedman, <i>UPenn</i>	14:30-15:00 [O2.3] BEAT-HIV Collaboratory: Path to a Cure. Luis Montaner, <i>Wistar Institute</i>	[O3.4] Broadly Protective Influenza Vaccines: Protection against mismatch – bettering standard of care. Harold Kleanthous, <i>Sanofi-Pasteur</i>

14:45-15:00	[O1.5] Decoding Immune Evading Mechanisms of pathogens: reordering of immunodominance for new and improved vaccines Peter Nara, <i>Biological Mimetics</i>	14:30-15:00 [O2.3] BEAT-HIV Collaboratory: Path to a Cure. Luis Montaner, <i>Wistar Institute (Continued)</i>	[O3.5] Pathologic and Immunologic characteristics of Coxsackievirus A16 infection in rhesus macaques. Ying Zhang, <i>Chinese Academy of Medical Sciences</i>
15:00-15:15	[O1.6] LAMP-based DNA vaccines suppress IgE production and intestinal anaphylaxis in a murine model of Peanut-induced Food Allergy Franco Pissani, <i>Immunomics Therapeutic,</i>	[O2.4] Two doses of a DNA Vaccine Expressing the Glycoprotein Precursor Gene of Lassa Virus Fully Protect Nonhuman Primates from Lassa Fever when Delivered by Dermal Electroporation Kathleen Cashman, <i>USAMRIID</i>	[O3.6] An optimized synthetic DNA vaccine targeting liver stage exported proteins provides sterilizing protection from <i>P. yoelii</i> sporozoite challenge. Emma Reuschel, <i>Wistar Institute</i>
15:15-15:30	[O1.7] Microneedle-based cutaneous immunotherapy for allergy treatment Akhilesh Kumar Shakya, <i>Texas Tech Univ.</i>	[O2.5] Comparative evaluation of electroporation mediated intradermal or intramuscular administration of DNA vaccines against the Venezuelan, eastern, and western encephalitic alphaviruses. Drew Hannaman, <i>Ichor Med. Sys.</i>	[O3.7] Identification and validation of immunodominant antigens as protective prophylactic against <i>Shigella</i>. Bhругu Yagnik, <i>Sardar Patel University</i>
15:30-16:00	Coffee Break (Foyer of Grand Ballroom)		Sponsored by Pfizer Inc
16:00-18:00	Plenary Session 2: Insights into the Immunology of Vaccines and Immunotherapy Session Chairs: Adolfo Garcia-Sastre and Anna-Lise Williamson		
16:00-16:30	[O9.9] Upper Respiratory Tract (URT) Administration of a Replication-Competent Ad4-H5-Vtn Vaccine Induces Durable Neutralizing Antibody Responses in Humans. Mark Connors, <i>LIR, NIAID</i>		
16:30-17:00	[PL2.2] A Replication Defective Human Cytomegalovirus Vaccine for Prevention of Congenital Infection Tong-Ming Fu, <i>Merck</i>		
17:00-17:15	[PL2.3] Adjuvants play a critical role in universal influenza vaccine design Nik Petrovsky, <i>Flinders University</i>		
17:15-17:30	[PL2.4] Side-Stepping Regulatory T Cell Induction to Build Better Vaccines Anne De Groot, <i>EpiVax, Univ. of Rhode Island</i>		
17:30-17:45	[PL2.5] An Optimized, Synthetic DNA Vaccine Encoding the Toxin A/Toxin B RBDs of <i>Clostridium difficile</i> Induces Protective Antibody Responses. Michele Kutzler, <i>Drexel Univ.</i>		
17:45-18:00	[PL2.6] A subunit protein based therapeutic vaccine design to treat Genital Herpes disease and subclinical infection in a pre-clinical model. Sita Awasthi, <i>Univ. Penn.</i>		
18:15-20:00	Poster Session and Reception (Palm Garden)		
Monday, 3 October 2016			
08:00-18:00	Registration		
08:00-10:00	Plenary Session 3: Global Health Issues and Vaccine Approaches Session Chairs: William Jacobs and Yvonne Maldonado		
08:00-0830	[PL3.1] Keynote speech, Biosecurity and winning the war against future epidemics Victor Dzau, <i>National Academy of Medicine, US National Academy of Sciences</i>		
08:30-09:00	[PL3.2] AIDS, Avian flu, SARS, MERS, Ebola, Zika ...what next? Ab Osterhaus, <i>Univ. Veterinary Medicine Hannover</i>		
09:00-09:30	[PL3.3] The Power of Cryptic Epitopes in Designing Vaccines Michael Good, <i>Griffith Univ.</i>		
09:30-09:45	[PL3.4] Clinical Development of Novel Conserved Element HIV pDNA Vaccine Able to Maximize Breadth and Magnitude of Immune Responses. Barbara Felber, <i>NCI</i>		
09:45-10:00	[PL3.5] Unitizing MVA-VLP platform for development of single dose vaccines: Tetravalent vaccine against hemorrhagic fever and Zika viruses. Farshad Guirakhoo, <i>GeoVax</i>		

10:00-10:30	Coffee Break (Foyer of Grand Ballroom)		
	Sponsored By Nature Technology Corporation		
10:30-12:45	Concurrent Session 4: Institut Pasteur Special Session Session Chairs: Christiane Gerke and Shan Lu	Concurrent Session 5: Vaccines and Biologicals: Production and Efficacy Session Chairs: Phil Krause and Britta Wahren	Concurrent Session 6: JSV/KVS: Adjuvant and Immunomodularity Principles for Mucosal vs. Systemic Immunity Session Chairs: Hiroshi Kiyono and Baik Lin Seong
10:30-11:00	[O4.1] Challenges and opportunities of yellow fever vaccination in Africa: Implications and lessons for Global Health. Amadou Alpha Sall, <i>Institut Pasteur, Dakar, Senegal</i>	[O5.1] Plant Production of Vaccines Ed Rybicki, <i>Univ. of Cape Town</i>	[O6.1] Herpes Zoster Subunit Vaccine – Overcoming Immunosenescence in the Elderly. Tom Heineman, <i>GSK</i>
11:00-11:30	[O4.5] Synthetic carbohydrate-based conjugates as vaccines: a promising concept illustrated for <i>Shigella</i> Laurence Mulard, <i>Institut Pasteur, Paris, France</i>	[O5.2] Ebola Zaire vaccine manufacturing using Janssen’s Adenovirus platform in response to global public health emergency and beyond. Joanke Graveland-Bikker, <i>Janssen</i>	[O6.2] Flagellin as a versatile adjuvant for mucosal vaccines. Joon Haeng Rhee, <i>Chonnam Nat’l. Univ.</i>
		[O5.3] Expanding Global Vaccine Availability Through Supported Technology Transfer to DCVM- The IVI Experience Julia Lynch, <i>IVI</i>	
11:30-12:00	[O4.3] Vaccinology at Institut Pasteur Christiane Gerke, <i>Institut Pasteur, Paris, France</i>	[O5.4] Boosting vaccine development for infectious diseases of low and middle income countries. Allan Saul, <i>GSK Vaccines Inst.</i>	[O6.3] A system vaccinological approach to vaccine and adjuvant safety: establishment of a novel safety evaluating system. Eita Sasaki, <i>National Inst. of Infectious Disease</i>
		[O5.5] ChimeriVax-based Zika vaccine, a live-attenuated approach. Fernando Diaz, <i>Sanofi-Pasteur</i>	[O6.4] Adjuvant Formulations and Delivery Platforms Influence the Antibody Responses to Trimeric gp145 and gp120 HIV-1 Envelope Proteins. Mangala Rao, <i>Walter Reed Army Inst.</i>
12:00-12:15	[O4.4] Towards a broadly protective polyvalent virus-like particle vaccine against hand, foot and mouth disease. Xia Jin, <i>Institut Pasteur Shanghai, Shanghai, China</i>	[O5.6] DNA-delivery of monospecific and bispecific monoclonal antibodies targeting <i>Pseudomonas aeruginosa</i> expresses functional antibodies that protect mice in a lethal model of pneumonia. Ami Patel, <i>Wistar Institute</i>	[O6.5] Poly-IC synergizes with OX40 to enhance Ag-specific CD4 T cell response. Paurvi Shinde, <i>U. Conn</i>

12:15-12:30	[O4.2] Development of live measles vaccine vector for new emerging pathogens. Frédéric Tangy, <i>Institut Pasteur, Paris, France</i> <i>Presented by Christiane Gerke</i>	[O5.7] Electroporation-Mediated DNA Administration as an Antibody Delivery Platform for Passive Immunoprophylaxis. Claire Evans, <i>Ichor Medical Systems</i>	[O6.6] Amyloid-inspired Synthetic Peptide Hydrogels as Vaccine Adjuvants. Jai Rudra, <i>U. Texas Med. Branch</i>
12:30-12:45	[O4.6] A promising vaccine against bubonic and pneumonic plague Anne Derbise, <i>Institut Pasteur, Paris, France</i>	[O5.8] Yeast-produced recombinant virus-like particles of coxsackievirus A6 elicited protective antibodies in mice. Yu Zhou, <i>Shanghai Univ.</i>	[O6.7] Sulfated Archaeal Glycolipids as a Safe & Effective Vaccine Adjuvant for Induction of Cell-mediated Immunity. Michael McCluskie, <i>Nat'l. Res. Council Canada</i>
12:45-13:45	Lunch (Harbor View Ballroom and Commonwealth Ballroom) Sponsored By VGXI		
13:15-14:15	Poster Session 2 (Palm Garden)		
14:15-15:00	ISV Annual Meeting (Grand Ballroom)		
15:00-15:30	Coffee Break (Foyer of Grand Ballroom) Sponsored By Eurogentec		
15:30-17:45	Plenary Session 4: Immunization of Individuals in Special Physiological Circumstances Session Chairs: Sam Katz and Jeffrey Ulmer		
15:30-16:00	[PL4.1] Issues for the Endgame of Polio Eradication and the limitations of the Immunogenicity of OPV Yvonne Maldonado, <i>Stanford Univ.</i>		
16:00-16:30	[PL4.2] Maternal Immunization Flor Munoz, <i>Baylor College of Medicine</i>		
16:30-17:00	[PL4.3] Group B streptococcus vaccination in pregnant women with or without HIV in Africa Clare Cutland, <i>Univ. of the Witwatersrand</i>		
17:00-17:15	[PL4.4] Replication-defective lymphocytic choriomeningitis virus vectors expressing HPV16 antigens for therapeutic vaccination and cancer immunotherapy. Anders Lilja, <i>Hookipa Biotech</i>		
17:15-17:30	[PL4.5] Regression of Advanced Cervical Dysplasia and Elimination of HPV16/18 Infection by VGX-3100 is Statistically Associated with the Presence of Highly Active Peripheral Lytic CD8+ T cells and Cervical Immune Infiltration. Kimberly Kraynyak, <i>Inovio</i>		
17:30-17:45	[PL4.6] A Novel Heroin Conjugate Vaccine Abrogates Nociceptive and Behavioral Effects of Heroin through the Induction of High Titer and High Affinity Antibodies to Heroin and Its Degradation Products. Gary Matyas, <i>Walter Reed Army Inst. of Research</i>		
19:00-22:00	ISV Congress Dinner (New England Aquarium – tickets required)		
Tuesday, 4 October 2016			
08:00-14:00	Registration		
08:00-10:00	Plenary Session 5: Insights into Vaccine Targets and Effective Immune Responses Session Chairs: Flor Munoz and Marie-Paule Kieny		
08:00-08:30	[PL5.1] Factors Affecting Vaccine Investment by Companies Luis Jodar, <i>Pfizer</i>		
08:30-09:00	[PL5.2] Novel Biomarkers for antibody-directed effector function predicting vaccine efficacy. Galit Alter, <i>Harvard Medical School/MIT</i>		
09:00-09:15	[PL5.3] Different Strains of Recombinant <i>Mycobacterium bovis</i> Bacillus Calmette–Guérin (BCG) Expressing HIV Gag Prime Different Types of Immune Responses When Boosted with SAAVI MVA-C. Anna-Lise Williamson, <i>U. Cape Town</i>		
09:15-09:30	[PL5.4] Env-specific Rabbit Antibody-Mediated ADCC Activities vis Human Fc-Receptor. Shixia Wang, <i>UMMS</i>		
09:30-09:45	[PL5.5] Elimination of HIV from infected cells by IgG-conjugated enfuvirtide. Britta Wahren, <i>Karolinska Inst.</i>		
09:45-10:00	[PL5.6] Conformation of a Protein in Virus-like Particles Impacts their Efficacy as Vaccines. Trudy Morrison, <i>UMMS</i>		
10:00-10:30	Coffee Break (Foyer of Grand Ballroom) Sponsored By Regeneron		

10:30-12:45	Concurrent Session 7: New and Transformed Vaccine Technologies (KVS/JSV session) Session Chairs: Joon Rhee and Julia Lynch	Concurrent Session 8 : Emerging and Re-emerging Diseases; VaxRen Session Session Chairs: Anne De Groot and Connie Schmaljohn	Concurrent Session 9: Vaccines Against Respiratory Pathogens Session Chairs: Ted Ross and Linda Klavinskis
10:30-11:00	<p>[O7.1] Can serum vibriocidal antibodies mediate bactericidal activity against <i>Vibrio cholerae</i> O1 in the small intestine of persons recovered from wild type cholera and in recipients of live oral vaccine? Myron Levine, <i>Center for Vaccine Development, Univ. of Maryland</i></p>	<p>[O8.1] Q Fever; Immune Profiling of <i>Coxiella burnetii</i> Vaccination and Infection by Mass Cytometry Mark Pozansky, <i>Mass. General Hospital</i>, Patrick Reeves, <i>Mass General Hospital</i></p>	<p>[O9.1] A New Genome-Wide Antigen Discovery Algorithm Identifies Novel In-Vivo Expressed Mycobacterium Tuberculosis (IVE-TB) Antigens Inducing Human T Cell Responses with Classical and Unconventional Cytokine Secretion Profiles. Mariateresa Coppola, <i>Leiden Univ.</i></p> <p>[O9.2] Both young and aged effector CD4 T cells that recognize cognate Ag at the "memory checkpoint" differentiate to Tfh and memory cells and promote B cell memory in a vaccine model. Jingya Xia, <i>UMMS</i></p>
11:00-11:15	<p>[O7.2] A novel RSV vaccine elicits humoral and Treg-cell responses against RSV infection and suppresses vaccine enhanced disease (VED). Bin Wang, <i>Fudan Univ.</i></p>	<p>[O8.2] Ebola Challenge Study in Non-Human Primates: Role in Supporting the Development of rVSV-EBOV Vaccine. Amy Shurtleff, <i>USAMRIID</i></p>	<p>[O9.3] Characterization of Influenza Elicited Humoral Immunity in the domestic Ferret. Greg Kirchenbaum, <i>U. Georgia</i></p>
11:05-11:30	<p>[O7.3] Green tea catechin-inactivated viral vaccine. Baik Lin Seong, <i>Yonsei Univ.</i></p>	<p>[O8.3] A Phase 1 Study of a DNA Vaccine for Venezuelan Equine Encephalitis Delivered by Intramuscular or Intradermal Electroporation. Lesley Dupuy, <i>USAMRIID</i></p>	<p>[O9.4] Development of a safe, tolerable and efficacious gene-based immunoprophylaxis delivery strategy to protect against RSV. Trevor Smith, <i>Inovio</i></p>
11:30-11:45	<p>[O7.4] Preclinical evaluation of hemagglutinin stalk-based candidate universal influenza vaccines in ferrets. Randy Albrecht, <i>Mount Sinai Med. School</i></p>	<p>[O8.4] Confirmation of a lethal mouse model for Zika virus infection and development of a novel DNA vaccine that is fully protective against lethal infection in vivo. Trina Racine, <i>Canadian Science Centre for Human and Animal Health</i></p>	<p>[O9.5] Formulation of the RSV fusion protein with a novel combination adjuvant mediates the induction of long-term immune memory and disease protection. Sylvia Van Den Hurk, <i>VIDO-Intervac</i></p>
11:45-12:00	<p>[O7.5] An alternative platform for the development of live attenuated influenza virus vaccines. Jefferson Santos, <i>U. Georgia</i></p>	<p>[O8.5] Identification of dengue-specific and cross-reactive B cells using labeled viruses following natural infection and vaccination. Anuja Mathew, <i>U. Rhode Island</i></p>	<p>[O9.6] Broad Cross-Protective Anti-Hemagglutination Responses Elicited by Influenza Micro-Consensus DNA Vaccine. Jian Yan, <i>Inovio</i></p>
12:00-12:15	<p>[O7.6] A heterologous prime-boost vaccine regimen induces long-lasting neutralizing antibody response capable of preventing Ebola virus-like particle entry in mice. Dapeng Li, <i>Inst. Pasteur</i></p>	<p>[O8.6] A novel tetravalent formulation combining the four aggregated domain III-capsid proteins from dengue viruses induces a functional immune response in mice and monkeys. Lázaro Gil González, <i>Ctr. Genetic Engr. Biotech</i></p>	<p>[O9.7] Design and Characterization of a COBRA H1N1 HA Vaccine in a Pre-Immune Ferret Model. Donald Carter, <i>U. Georgia</i></p>

12:15-12:30	[O7.7] Perspectives of a tumor vaccine based on attenuated <i>Listeria monocytogenes</i> for prevention and treatment of hepatocellular carcinoma. Tetyana Yevesa, MHH, <i>Hannover</i>	[O8.7] Extreme Polyvalency Induces Potent Cross-Clade Cellular and Humoral Responses in Rabbits and Non-human Primates Megan Wise, <i>UPenn, Wistar Institute</i>	[O9.8] Efficacy of Adenovirus Vector-Based Multi-Epitope Vaccine against A/H5, A/H7, and A/H9 Avian Influenza Viruses. Ahmed Hassan, <i>Purdue Univ.</i>
12:30-12:45	[O7.8] Novel recombinant HIV vaccine candidates based on replication-defective flavivirus vectors demonstrate favorable safety and immunogenicity profile in NHP. Maryann Giel-Moloney, <i>Sanofi-Pasteur</i>	[O8.8] Vaccines against Middle East Respiratory Syndrome Coronavirus (MERS-CoV) elicit humoral and cellular immune responses in mice Naif Alharbi, <i>Univ. of Oxford, King Abdullah International Medical Research Center</i>	[P80] Single-Cycle Adenoviruses (SC-Ads) as Antigen Gene Amplifying Vaccines Michael Barry, <i>Mayo Clinic</i>
12:45-13:45	Lunch (<i>Harbor View Ballroom and Commonwealth Ballroom</i>) Sponsored By Invoio Pharmaceuticals		
13:00-13:45	Career Development Panel: Laina King, NIH, Shan Lu, UMASS, Annie De Groot, URI/EpiVax, Nicola Lamonica, Johnson & Johnson Innovation <i>(Commonwealth Room)</i>		
13:45-14:00	ISV Award Ceremony (<i>Grand Ballroom</i>)		
14:00-16:00	Plenary Session Six: One Health and Emerging Diseases Session Chairs: David Weiner and Margaret Liu		
14:00-14:30	[PL6.1] Lessons Learned from Ebola R & D during a Health Emergency Marie-Paule Kieny, <i>World Health Organization</i>		
14:30-15:00	[PL6.2] Lessons Learned from Sanofi Pasteurs Dengue Vaccine Program and Challenges for Zika Nick Jackson, <i>Sanofi Pasteur</i>		
15:00-15:15	[PL6.3] ZMAPP, VSV-ZEBO Gary Kobinger, <i>Laval Univ.</i>		
15:15-15:30	[PL6.4] Rabies Vector for Ebola; NHP studies. Drishya Kurup, <i>Thomas Jefferson Univ.</i>		
15:30-15:45	[PL6.5] Clinical Assessment of a Bivalent DNA Vaccine for Hemorrhagic Fever with Renal Syndrome Caused by Hantavirus Infections. Connie Schmaljohn, <i>USAMRIID</i>		
15:45-16:00	[PL6.6] Discovery of <i>Toxoplasma Gondii</i> Vaccine Candidate Antigen. Mert Doskaya, <i>Ege Univ.</i>		
16:00-16:15	Closing Remarks and Introduction of 2017 ISV Annual Congress (<i>Grand Ballroom</i>)		